The flow cytometry-based “Mediators of apoptosis combinatorial score” (MAC-Score) incorporates a combination of the expression of the abovementioned BCL2 family members, reliably predicting the response of AML patients to VEN-AZA. This evidence concerns the gene BCL2 and acute myeloid leukemia.